Ascendis Pharma A/S (FRA:A71)
194.00
+4.00 (2.11%)
At close: Feb 20, 2026
Ascendis Pharma Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 616.04 | 559.54 | 392.16 | 444.77 | 446.27 |
Short-Term Investments | - | - | 7.28 | 290.69 | 235.8 |
Cash & Short-Term Investments | 616.04 | 559.54 | 399.44 | 735.46 | 682.06 |
Cash Growth | 10.10% | 40.08% | -45.69% | 7.83% | -5.11% |
Accounts Receivable | 141.33 | 166.28 | 35.87 | 11.91 | 2.2 |
Other Receivables | 16.36 | 11.16 | 19.9 | 13.72 | 20.99 |
Receivables | 157.7 | 177.44 | 55.77 | 25.63 | 23.19 |
Inventory | 301.53 | 295.61 | 208.93 | 130.67 | 75.41 |
Prepaid Expenses | 33.72 | 28.27 | 38.58 | 31.72 | 25.23 |
Total Current Assets | 1,109 | 1,061 | 702.72 | 923.47 | 805.89 |
Property, Plant & Equipment | 146.48 | 98.71 | 110.63 | 129.1 | 126.05 |
Long-Term Investments | 32.53 | 13.58 | 5.69 | 30.42 | 145.91 |
Goodwill | 3.5 | 3.5 | 3.5 | - | 3.5 |
Other Intangible Assets | 0.22 | 0.53 | 0.92 | 4.83 | 1.78 |
Other Long-Term Assets | 10.87 | 2.32 | 2.13 | 1.92 | 1.81 |
Total Assets | 1,303 | 1,179 | 825.59 | 1,090 | 1,085 |
Accounts Payable | 90.66 | 96.39 | 94.57 | 101.03 | 59.42 |
Accrued Expenses | - | - | 41.18 | 31.99 | 29.95 |
Current Portion of Long-Term Debt | 466.09 | 476.05 | 407.1 | 399.19 | - |
Current Portion of Leases | 20.44 | 15.48 | 14.17 | 13.79 | 7 |
Current Income Taxes Payable | 6.43 | 1.22 | 2.3 | 5.49 | 0.2 |
Current Unearned Revenue | 4.94 | 0.94 | 1.18 | - | 2.6 |
Other Current Liabilities | 480.83 | 317.78 | 176.02 | 165.29 | 1.19 |
Total Current Liabilities | 1,069 | 907.86 | 736.51 | 716.78 | 100.36 |
Long-Term Debt | 254.17 | 287.53 | 138.38 | - | - |
Long-Term Leases | 131.09 | 77.55 | 84.62 | 95.4 | 97.97 |
Long-Term Unearned Revenue | 1.12 | 5 | 5.95 | 14.21 | 2.96 |
Long-Term Deferred Tax Liabilities | 9.62 | 7.26 | 5.83 | - | - |
Total Liabilities | 1,465 | 1,285 | 971.28 | 826.39 | 201.29 |
Common Stock | 8.32 | 8.15 | 7.75 | 7.68 | 7.65 |
Additional Paid-In Capital | 2,531 | 2,444 | 2,123 | 2,113 | 2,108 |
Retained Earnings | -2,700 | -2,560 | -2,277 | -1,860 | -1,236 |
Treasury Stock | -0.08 | -0.11 | -0.15 | -0.15 | -0.02 |
Comprehensive Income & Other | -1.76 | 1.78 | 0.72 | 3.45 | 3.78 |
Shareholders' Equity | -162.82 | -105.71 | -145.7 | 263.35 | 883.64 |
Total Liabilities & Equity | 1,303 | 1,179 | 825.59 | 1,090 | 1,085 |
Total Debt | 871.79 | 856.62 | 644.27 | 508.38 | 104.96 |
Net Cash (Debt) | -255.75 | -297.07 | -244.83 | 234.57 | 684.66 |
Net Cash Growth | - | - | - | -65.74% | -7.74% |
Net Cash Per Share | -4.22 | -5.13 | -4.35 | 4.18 | 12.50 |
Filing Date Shares Outstanding | 61.38 | 59.84 | 56.61 | 56.04 | 56.78 |
Total Common Shares Outstanding | 61.38 | 59.84 | 56.61 | 56.04 | 56.78 |
Working Capital | 39.59 | 153 | -33.79 | 206.69 | 705.53 |
Book Value Per Share | -2.65 | -1.77 | -2.57 | 4.70 | 15.56 |
Tangible Book Value | -166.53 | -109.73 | -150.12 | 258.52 | 878.36 |
Tangible Book Value Per Share | -2.71 | -1.83 | -2.65 | 4.61 | 15.47 |
Machinery | 37.62 | 32.91 | 38.86 | - | 25.77 |
Leasehold Improvements | 7.05 | 20.3 | 19.38 | - | 18.07 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.